Evidence map›Paper›PMID 41079522›Full record

ArticleThe mental health clinician2025

Xanomeline/trospium-induced polyuria: A patient case report.

Henry Leach, Francesca DiGuglielmo

Abstract readCase Reports
In one paragraph

Article in The mental health clinician, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Henry LeachClinical Coordinator, PGY-2 Psychiatric Pharmacy Residency Program Director, Toms River New Jersey.ORCID https://orcid.org/0000-0003-1142-9868
Francesca DiGuglielmo(Corresponding author) PGY-2 Psychiatric Pharmacy Resident, Toms River, New Jersey, francesca.diguglielmo@rwjbh.org.ORCID https://orcid.org/0009-0001-9175-4881

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Xanomeline/trospium is a newly approved agent for the management of schizophrenia. Unlike traditional antipsychotics, which are D

Indexed as

cholinergic effectsmuscarinic receptor agonistpolyuriaschizophreniaxanomeline/trospium

Identifiers

PMID41079522
PMCPMC12510629

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.